Ovarian cancer
Therapeutic area
Oncology
Rare disease
Yes
- Definition
- A primary or metastatic malignant neoplasm involving the ovary. Most primary malignant ovarian neoplasms are either carcinomas (serous, mucinous, or endometrioid adenocarcinomas) or malignant germ cell tumors. Metastatic malignant neoplasms to the ovary include carcinomas, lymphomas, and melanomas.
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Ovarian cancer
- Therapeutic area
- Oncology
- ovarian cancer
- ovarian neoplasm
- ovary neoplasm
- tumor of the ovary
- tumour of the ovary
- cancer of ovary
- cancer of the ovary
- malignant neoplasm of ovary
- malignant neoplasm of the ovary
- malignant ovarian neoplasm
- malignant ovarian tumor
- malignant ovarian tumour
- malignant ovary neoplasm
- malignant tumor of ovary
- malignant tumor of the ovary
- malignant tumour of ovary
- malignant tumour of the ovary
- ovarian cancer
- ovarian cancer, somatic
- ovarian malignant tumor
- ovarian malignant tumour
- ovary cancer
- Severity
- Severe
- Endocrinology
- Oncology
- Reproductive Health
- MONDO ID
- MONDO:0008170
- Parent condition
- MONDO:0001416
Related records
Broader conditions (18)
- Cancer
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Endocrine system disorder
- Female reproductive organ cancer
- Female reproductive system disorder
- Female reproductive system neoplasm
- Gonadal disorder
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
- Ovarian disorder
- Ovarian neoplasm
- Reproductive system cancer
- Reproductive system disorder
- Reproductive system neoplasm
Narrower conditions (77)
- Childhood choriocarcinoma of the ovary
- Childhood immature teratoma of ovary
- Childhood ovarian embryonal carcinoma
- Childhood ovarian yolk sac tumor
- Choriocarcinoma of ovary
- Dysgerminoma of ovary
- Familial ovarian cancer
- Familial ovarian carcinoma
- Gestational ovarian choriocarcinoma
- Hereditary site-specific ovarian cancer syndrome
- Hypercalcemic type ovarian small cell carcinoma
- Immature ovarian teratoma
- Krukenberg carcinoma
- Liposarcoma of the ovary
- Maligant granulosa cell tumor of ovary
- Malignant dysgerminomatous germ cell tumor of ovary
- Malignant epithelial tumor of ovary
- Malignant germ cell tumor of ovary
- Malignant non-dysgerminomatous germ cell tumor of ovary
- Malignant non-epithelial tumor of ovary
Trials (2,399)
- 'OLAP' (OLAparib Regulatory Post-marketing Surveillance)
- (GI-RADS) in Preoperative Evaluation of Adnexal Masses
- (VELA) Study of BLU-222 in Advanced Solid Tumors
- [18F]-AZAFOL AS POSITRON EMISSION TOMOGRAPHY (PET) TRACER in FR Positive Cancer Imaging
- [68Ga]Ga-FAPI-46 PET/CT in Ovarian Cancer
- 11C Topotecan PET Imaging
- 13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.
- 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
- 18F-ASIS PET/CT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer
- 18F-CP18 Imaging Studies for Cancer Treatment With Birinapant
- 18F-DCFPyL PET/CT in High-grade Epithelial Ovarian Cancer (PET HOC)
- 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
- 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
- 3D Prediction of Patient-Specific Response
- 4FMFES-PET Imaging of Endometrial and Ovarian Cancers
- 68Ga-FAPI-PSMA PET Imaging for the Diagnosis of Solid Tumors
- 68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
- 89Zr-DFO-Mirvetuximab PET/CT Imaging for Companion Diagnosis and Response Evaluation in Ovarian Cancer
- A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse
Approved drugs (10)
- Amifostine
- Bevacizumab
- Carboplatin
- Doxorubicin hydrochloride
- Gemcitabine hydrochloride
- Olaparib
- Paclitaxel
- Rucaparib camsylate
- Topotecan hydrochloride
- Trabectedin
Drugs in development (368)
- 2X-121 Phase 2
- 4-isothioureidobutyronitrile Phase 2
- 9-aminocamptothecin Phase 2
- Abagovomab Phase 2
- Abituzumab Phase 1
- Acalabrutinib Phase 2
- Adagloxad simolenin Phase 2
- Adavosertib Phase 2
- Afuresertib Phase 2
- Aldesleukin Phase 2
- Alemtuzumab Phase 1
- Alendronic acid Phase 2
- Allopurinol Phase 2
- Alsevalimab Early phase 1
- Alvespimycin hydrochloride Phase 1
- Alvimopan Phase 3
- Amcasertib Phase 2
- Amonafide Phase 3
- Anastrozole Phase 3
- Anetumab ravtansine Phase 1
Other linked drugs (14)
- Altretamine
- Fenretinide
- Maplirpacept
- Melphalan flufenamide
- Mibefradil
- Mirvetuximab soravtansine
- Niraparib tosylate monohydrate
- Olvimulogene nanivacirepvec
- Parpi
- Pentetic acid
- Plicamycin
- Technetium TC 99M pentetate
- Ubamatamab
- XMT-1592